2bind Drug Discovery Services

Hit Identification

2bind is your one-stop shop for early drug discovery hit identification. We cover all required steps from Assay Development to Screening.

We provide in-house compound and bioactive tool compound librariers and access to fragment libraries.

High-throughput-scale liquid handling completes the early drug-discovery method pipeline.

Click here for a fragment-based drug discovery (FBDD) special!

Assay Development

All the right tools for the job!
We offer the full portfolio of state-of-the art biophysical assay development using MicroScale Thermophoresis and nanoDSF.
Our methods and assays are certified by NanoTemper Technologies.
Assay development covers assay setup, establishment, robustness testing, and transfer to a high-throughput setup.

Ligand Libraries

Biophysical hit screening made easy.
2bind’s partner-network gives you access to computational ligand pre-screening, high-fidelity fragment libraries for fragment-based drug discovery as well as specialized small molecule and bioactive tool compound collections.

Target- or ligand-based pre-screening using novel in silico fingerprint-based algorithms.

> Reduction of library size and complexity.

> Reduction of screening time and costs.

Flexible sourcing of specialized fragment libraries from partners and vendors.

> Tailored selection of library size.

> Specific selection of chemical space.

150.000 small molecule collection and 5050 bioactive tool compound collection from our partner Assay.Works.

> Seamless integration into our processes.

Liquid Handling

Save on your precious fragments and compounds!
We use ultrasound-based, direct dilution systems (LabCyte Echo platform) for fragment and compound handling.
This enables ultra-fast, contact-less, direct dilution of DMSO stocks with single-digit nL volumes.
No plastic ware used, no sample carryover, no cross-contamination, and absolut minimum compound consumption!

High-throughput screening

True biophysical high-throughput screening using MicroScale Thermophoresis (MST) and nanoDSF.
Don’t get only a yes-or-no answer for your fragments or compound. Get their true steady-state affinity.
MST and nanoDSF offer the absolute lowest sample consumption for biophysical screening on the market.
Screenings of thousand of compounds can be performed with just a couple of hundred microliters of protein solution.

100 full, 12-point dose-response curves in 10 hours with true steady-state affinity (KD) determination.

Up to 600 single-dose analyses in 10 hours.

> Online quality-controls (target instability, precipitation, and adhesion effects).

> Classification of binders, non-binders, fluorescent-effects, target-aggregation-inducing compounds, etc.

48 target-ligand pairs in parallel with determination of ligand-induced thermal shift of protein denaturation.

480 ligand analyses in 10 hours.

> Online quality-controls (target unfolding, ligand fluorescence).

> Identification of target-aggregation-inducing ligands possible by light scattering.

Hit Validation + Hit Characterization

 A number of biophysical paramters is of great intereset in the Hit Validation phase of a drug discovery projects. These include precise steady-state binding affinity to the screening target (KD), as well as the kinetic (kon, koff) and thermodynamic (ΔG, ΔH, ΔS) parameters of hit-target interactions. We cover all these questions with our portfolio of MST, nanoDSF, BLI, and ITC methods. 

In hit-to-lead stages, a lower number of drug candidates are typically analyzes with respect to more advanced binding parameters, like stoichiometry, possible competition effects, or their mode-of-action. Moreover, off-target effects have to be carefully investigated, for example by analyzing hit-target interactions in various biological liquids like serum, celly lysate, blood plasma, urine, or the like. Benefit from our higly-variable timelines and project setups to choose the right assay at the right time of the hit-to-lead phase, just as you like.

Contact Specialist